Genocury Biotech

Focus: Genocury Biotech is a China-based biotechnology company specializing in off-the-shelf cell and gene therapy development. Limited public information constrains assessment of market position and scale.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Genocury Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Genocury Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CD19/BCMA-targeted CAR-T lentiviral vector drug

Autoimmune Diseases

N/A

Clinical Trials (1)

NCT07490951Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases

N/A

Help build intelligence for Genocury Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in high-growth gene therapy segment with potential for significant impact in emerging markets
Headquarters in Shenzhen positions you at China's biotech innovation hub with access to regional resources and partnerships
Off-the-shelf cell therapy focus represents differentiated modality with lower manufacturing complexity than autologous approaches

Watch Out For

No active clinical trials reported suggests early preclinical stage with uncertain development timeline and regulatory clarity
Zero active job openings indicate company is not actively hiring or may face growth constraints

Generated by Claude from Genocury Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

JY231

Autoimmune Diseases

N/A

Clinical Trials (1)

NCT07059169CAR-T Therapy for Refractory Autoimmune Diseases

N/A

JY231 Injection

B-NHL

N/A

Clinical Trials (1)

NCT06678282JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

N/A